IP Verse

Mitsubishi Tanabe Pharma competitive analysis

Latest publications and patents of Mitsubishi Tanabe Pharma New

Explore the latest publications and patents granted to Mitsubishi Tanabe Pharma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Mitsubishi Tanabe Pharma

EP4549579
May 7, 2025Composition And Method For Evaluating Responsiveness Of EdaravoneRequest For Examination Was Made
EP3875085
Jun 19, 2024Edaravone Suspension For Oral AdministrationGranted And Under Opposition
EP2896397
Oct 7, 2020Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose TransporterPatent Maintained As Amended
EP2252289
Oct 23, 2019Combination Therapy Comprising Sglt Inhibitors And Dpp4 InhibitorsRevoked
EP2754440
Apr 3, 2019Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral SclerosisRevoked
EP1714960
Mar 28, 2018Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To AlsRevoked
EP2933248
Jan 31, 2018Novel Renin InhibitorNo Opposition Filed Within Time Limit
EP2842937
Jan 17, 2018Amine Compound And Use Thereof For Medical PurposesNo Opposition Filed Within Time Limit
EP2847324
Jan 3, 2018Rotavirus-Like Particle Production In PlantsNo Opposition Filed Within Time Limit

Latest patents of Mitsubishi Tanabe Pharma opposed by its competitors

Explore Mitsubishi Tanabe Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3875085
Jun 19, 2024Edaravone Suspension For Oral Administration1
EP2896397
Oct 7, 2020Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter2
EP2252289
Oct 23, 2019Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors1
EP2754440
Apr 3, 2019Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis1
EP1714960
Mar 28, 2018Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als1

Latest PTAB cases involving Mitsubishi Tanabe Pharma

Discover the latest PTAB cases involving Mitsubishi Tanabe Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Mitsubishi Tanabe Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
MITSUBISHI TANABE PHARMA - 6 - - Non-Active
ELKINGTON AND FIFE87 - - - Highly Aggressive
GALENICUM HEALTH SL112 - - Defensive
MAIWALD134 - - - Highly Aggressive